JP2018537949A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537949A5
JP2018537949A5 JP2018513634A JP2018513634A JP2018537949A5 JP 2018537949 A5 JP2018537949 A5 JP 2018537949A5 JP 2018513634 A JP2018513634 A JP 2018513634A JP 2018513634 A JP2018513634 A JP 2018513634A JP 2018537949 A5 JP2018537949 A5 JP 2018537949A5
Authority
JP
Japan
Prior art keywords
dendritic cell
tnfα
activated
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018513634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537949A (ja
JP6980650B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/051781 external-priority patent/WO2017048875A1/en
Publication of JP2018537949A publication Critical patent/JP2018537949A/ja
Publication of JP2018537949A5 publication Critical patent/JP2018537949A5/ja
Priority to JP2021186960A priority Critical patent/JP2022028818A/ja
Application granted granted Critical
Publication of JP6980650B2 publication Critical patent/JP6980650B2/ja
Priority to JP2023200819A priority patent/JP2024019229A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018513634A 2015-09-15 2016-09-14 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法 Active JP6980650B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021186960A JP2022028818A (ja) 2015-09-15 2021-11-17 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法
JP2023200819A JP2024019229A (ja) 2015-09-15 2023-11-28 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219058P 2015-09-15 2015-09-15
US62/219,058 2015-09-15
PCT/US2016/051781 WO2017048875A1 (en) 2015-09-15 2016-09-14 Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021186960A Division JP2022028818A (ja) 2015-09-15 2021-11-17 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法

Publications (3)

Publication Number Publication Date
JP2018537949A JP2018537949A (ja) 2018-12-27
JP2018537949A5 true JP2018537949A5 (https=) 2019-10-31
JP6980650B2 JP6980650B2 (ja) 2021-12-15

Family

ID=58289879

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018513634A Active JP6980650B2 (ja) 2015-09-15 2016-09-14 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法
JP2021186960A Withdrawn JP2022028818A (ja) 2015-09-15 2021-11-17 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法
JP2023200819A Pending JP2024019229A (ja) 2015-09-15 2023-11-28 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021186960A Withdrawn JP2022028818A (ja) 2015-09-15 2021-11-17 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法
JP2023200819A Pending JP2024019229A (ja) 2015-09-15 2023-11-28 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法

Country Status (16)

Country Link
US (1) US20190046568A1 (https=)
EP (2) EP3971285A3 (https=)
JP (3) JP6980650B2 (https=)
KR (1) KR20180044430A (https=)
CN (2) CN116413420A (https=)
AU (2) AU2016323066B2 (https=)
BR (1) BR112018005180B1 (https=)
CA (1) CA2998614A1 (https=)
DK (1) DK3350318T3 (https=)
ES (1) ES2923769T3 (https=)
HU (1) HUE059560T2 (https=)
IL (3) IL286225B2 (https=)
MX (2) MX393996B (https=)
PL (1) PL3350318T3 (https=)
RU (1) RU2749610C2 (https=)
WO (1) WO2017048875A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190076473A1 (en) * 2017-09-14 2019-03-14 Cellular Approaches, Inc. Autologous and allogenic macrophages and monocytes for use in therapeutic methods
CN110106145B (zh) * 2019-06-12 2021-02-12 蓝莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法
AU2020363707A1 (en) * 2019-10-07 2022-04-28 Northwest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
CN119286782B (zh) * 2024-12-11 2025-04-04 上海赛笠百傲生物医药有限公司 一种高效诱导外周血来源单核细胞至不成熟树突状细胞的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
WO2004000444A1 (en) 2002-06-19 2003-12-31 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for leukocyte enrichment
WO2004039968A1 (ja) * 2002-10-30 2004-05-13 Japan Science And Technology Agency 骨髄由来の不死化樹状細胞株
ES2354944T3 (es) * 2002-12-06 2011-03-21 Northwest Biotherapeutics, Inc. Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
ES2321939T3 (es) * 2003-02-27 2009-06-15 Northwest Biotherapeutics, Inc. Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citoquinas adicionales.
US20060257359A1 (en) * 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
KR20080109717A (ko) * 2005-12-08 2008-12-17 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한조성물 및 방법
JP5382529B2 (ja) * 2007-09-10 2014-01-08 独立行政法人理化学研究所 ヒト樹状細胞の評価方法およびヒト細胞免疫療法剤
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
MX2011012147A (es) * 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
CN103638517A (zh) * 2013-12-04 2014-03-19 深圳市合一康生物科技有限公司 人树突状细胞疫苗制备的专用试剂盒
WO2016048872A1 (en) * 2014-09-23 2016-03-31 Neostem Oncology, Llc Compositions, methods and kits used to determine potency of dendritic cells in cancer immunitherpay

Similar Documents

Publication Publication Date Title
Weiner The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
MacLeod et al. Memory CD4 T cells: generation, reactivation and re‐assignment
Araki et al. The role of mTOR in memory CD8+ T‐cell differentiation
Brunner et al. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
Santini et al. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity
JP5730577B2 (ja) 樹状細胞の作製方法
RU2005121256A (ru) Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей
Jelley‐Gibbs et al. Influencing the fates of CD4 T cells on the path to memory: lessons from influenza
EP1153122A2 (en) Maturation of dendritic cells with immune response modifying compounds
JP2016185956A (ja) 寛容原性療法のための細胞のプログラミングの方法
Naoe et al. Bacillus Calmette‐Guérin‐pulsed dendritic cells stimulate natural killer T cells and γδT cells
JP2008000001A (ja) 免疫刺激オリゴヌクレオチドおよびその医薬用途
JP2018537949A5 (https=)
McAleer et al. Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide
JP2018523996A5 (https=)
AU2023208190B2 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
Choi et al. The function of memory CD8+ T cells in immunotherapy for human diseases
RU2018103235A (ru) Оптимально активированные дендритные клетки, индуцирующие улучшенный или повышенный противоопухолевый иммунный ответ
Moll The role of dendritic cells at the early stages of Leishmania infection
Schattenberg et al. Response of human monocyte‐derived dendritic cells to immunostimulatory DNA
Daudelin et al. IL‐6 production by dendritic cells is dispensable for CD8+ memory T‐cell generation
KR20220098351A (ko) 수지상 세포 및 T 세포의 활성화를 증진시키고 Th-1 면역 반응을 유도하기 위한 시험관내 방법 및 조성물
EP1793678A1 (en) Dendritic cell tumor injection (dcti) therapy
JP5010280B2 (ja) ヒトリンパ球由来のワクチンアジュバント
Steinman et al. Dendritic cells: important adjuvants during DNA vaccination